中國蘇軒堂藥業股份有限公司 新增研發并生產葵花盤、豬膽粉等現代中藥飲片，鹿血晶產能持續增長

中(zhong)(zhong)國(guo)(guo)有(you)泰州，2022年(nian)1月14日(ri)(ri)/美通社/--細心于中(zhong)(zhong)醫(yi)(yi)(yi)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)物品，以及目(mu)前中(zhong)(zhong)醫(yi)(yi)(yi)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)（簡單口服(fu)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)和(he)泡服(fu)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)），特制(zhi)(zhi)中(zhong)(zhong)醫(yi)(yi)(yi)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)，普通型中(zhong)(zhong)醫(yi)(yi)(yi)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)和(he)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)食同源物品的(de)開發、工作、網(wang)絡營銷(xiao)和(he)經銷(xiao)商的(de)中(zhong)(zhong)醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)廠局(ju)(ju)(ju)限(xian)(xian)(xian)我司(si)(si)(si)－國(guo)(guo)內蘇(su)軒堂藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)業(ye)控股股東局(ju)(ju)(ju)限(xian)(xian)(xian)局(ju)(ju)(ju)限(xian)(xian)(xian)我司(si)(si)(si)(NASDAQ: SXTC)（也叫“蘇(su)軒堂藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)業(ye)”甚至“集團(tuan)裝(zhuang)修公(gong)司(si)(si)(si)”），今日(ri)(ri)公(gong)布集團(tuan)裝(zhuang)修公(gong)司(si)(si)(si)研制(zhi)(zhi)并向專業(ye)市(shi)場退出西藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)泡服(fu)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)葵(kui)花盤中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)和(he)直(zhi)接的(de)口服(fu)方式(shi)西藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)豬膽粉(fen)(fen)，泡服(fu)中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)葵(kui)花盤中(zhong)(zhong)葯(yao)(yao)(yao)(yao)材(cai)原則(ze)黑國(guo)(guo)家藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)監局(ju)(ju)(ju)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)注函【2020】34號《中(zhong)(zhong)老百(bai)姓中(zhong)(zhong)華共(gong)和(he)國(guo)(guo)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)典(dian)》（2020年(nian)版(ban)）四(si)部泡制(zhi)(zhi)管(guan)理(li)規范生產的(de)，含(han)有(you)清肺熱(re)平肝、通絡止(zhi)(zhi)疼的(de)的(de)功效(xiao)，適在(zai)于頭暈目(mu)眩、耳(er)鳴(ming)、膝蓋各種(zhong)痛(tong)感及高(gao)尿酸(suan)高(gao)血癥、痛(tong)風發作、心腦血管(guan)病偏高(gao)等(deng)現(xian)象；就(jiu)直(zhi)接口服(fu)方式(shi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)丹參飲(yin)豬膽粉(fen)(fen)遵循(xun)原則(ze)《中(zhong)(zhong)國(guo)(guo)國(guo)(guo)人艮中(zhong)(zhong)華共(gong)和(he)國(guo)(guo)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)典(dian)》（2020年(nian)版(ban)）中(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)炮制(zhi)(zhi)標準，具備(bei)著清火(huo)清熱(re)去火(huo)，化痰止(zhi)(zhi)咳平喘，祛毒的(de)功效(xiao)，符合于頓咳、心臟(zang)病、熱(re)病燥渴(ke)、目(mu)赤、喉痹、黃疸高(gao)、泄瀉、痢疾、大便不(bu)順暢、瘡癰腫毒等(deng)不(bu)適反應，豬膽粉(fen)(fen)中(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)被歸入(ru)祖國(guo)(guo)的(de)醫(yi)(yi)(yi)保(bao)報(bao)銷(xiao)報(bao)銷(xiao)的(de)子目(mu)錄領域（祖國(guo)(guo)的(de)醫(yi)(yi)(yi)保(bao)報(bao)銷(xiao)報(bao)銷(xiao)的(de)子目(mu)錄順序(xu)號697），預期豬膽粉(fen)(fen)丹參飲(yin)和(he)葵(kui)花盤丹參飲(yin)生產能量(liang)均可到達30萬(wan)瓶，并開展在(zai)截止(zhi)(zhi)日(ri)(ri)2023年(nian)3月31日(ri)(ri)財年(nian)組成約(yue)500千元銷(xiao)售(shou)量(liang)。

其它，大(da)公司(si)在(zai)2021年(nian)6月(yue)18日(ri)(ri)受(shou)最近很多用戶問我，說河南省(sheng)進(jin)口醫療(liao)藥(yao)品遠(yuan)程監控維護局造(zao)成其新凍(dong)干(gan)種植生(sheng)(sheng)活設施所確定的進(jin)口醫療(liao)藥(yao)品GMP正規性查檢(jian)的后果(guo)，加(jia)工(gong)時間(jian)(jian)是有(you)了延遲，生(sheng)(sheng)產能(neng)力受(shou)其后果(guo)比(bi)同(tong)一時間(jian)(jian)有(you)了減(jian)低。2021年(nian)6月(yue)20日(ri)(ri)，安徽(hui)省(sheng)進(jin)口藥(yao)品監督(du)的菅理職能(neng)菅理局集團實(shi)現了對集團的GMP合規管(guan)理性檢(jian)查。載(zai)止2021年(nian)12月(yue)31日(ri)(ri)，食用冷藏干(gan)燥處(chu)理加(jia)工(gong)過程產出(chu)的會口服方式草藥(yao)中(zhong)藥(yao)材服務鹿血(xue)晶(jing)共12個(ge)批號(hao)，工(gong)司(si)投(tou)放化學原料(liao)鹿血(xue)2.08噸，冰凍(dong)烘(hong)干(gan)實(shi)現鹿血(xue)晶(jing)總金額316.92kg，預測在(zai)截至(zhi)2022年(nian)3月(yue)31日(ri)(ri)財年(nian)可演變(bian)成推廣300二(er)百(bai)多萬，現在(zai)鹿血(xue)晶(jing)市揚具(ju)體需求的不間(jian)(jian)斷增大(da)，有(you)限公司(si)生(sheng)(sheng)產量生(sheng)(sheng)產量也將轉變(bian)成迅速的延長走勢。

司研發管理行業重要(yao)依據直接(jie)性(xing)口服(fu)(fu)方(fang)式(shi)(shi)(shi)中(zhong)(zhong)醫飲(yin)(yin)(yin)片的(de)(de)舉(ju)例(li)，進(jin)行《中(zhong)(zhong)國(guo)現(xian)代(dai)藥典(dian)》2015版(ban)一個(ge)合(he)理中(zhong)(zhong)藥方(fang)中(zhong)(zhong)藥材(cai)的(de)(de)「煅法」、「使用(yong)(yong)(yong)」項下的(de)(de)規范(fan)化，按FDA、CFDA有(you)(you)(you)關(guan)仿制(zhi)藥監床前的(de)(de)開發方(fang)案，app新(xin)的(de)(de)現(xian)當(dang)代(dai)創新(xin)科技、鉆研和定性(xing)分析工(gong)藝及科技，依中(zhong)(zhong)葯中(zhong)(zhong)要(yao)制(zhi)劑(ji)的(de)(de)性(xing)能(neng)指標，系統化地開發的(de)(de)之類(lei)最新(xin)型(xing)隨時(shi)口服(fu)(fu)方(fang)式(shi)(shi)(shi)方(fang)式(shi)(shi)(shi)中(zhong)(zhong)葯中(zhong)(zhong)要(yao)制(zhi)劑(ji)物料款型(xing)，擁有(you)(you)(you)沒有(you)(you)(you)煎煮(zhu)只能(neng)隨時(shi)口服(fu)(fu)方(fang)式(shi)(shi)(shi)方(fang)式(shi)(shi)(shi)或沖服(fu)(fu)、增加原始的(de)(de)所有(you)(you)(you)有(you)(you)(you)效率(lv)營養成(cheng)分因此提升監床效用(yong)(yong)(yong)、運行和隨身攜帶(dai)簡(jian)單方(fang)便、開源(yuan)節流名貴(gui)中(zhong)(zhong)藥材(cai)、易會(hui)自動儲(chu)存等優點。中(zhong)(zhong)西藥泡(pao)服(fu)(fu)中(zhong)(zhong)藥飲(yin)(yin)(yin)片獨(du)一起造(zao)成(cheng)在《中(zhong)(zhong)國(guo)國(guo)藥典(dian)》2015版(ban)四部(bu)(bu)的(de)(de)另幾大類(lei)類(lei)新(xin)技術的(de)(de)、快(kuai)速(su)可用(yong)(yong)(yong)滾(gun)水(shui)沖奶粉飲(yin)(yin)(yin)用(yong)(yong)(yong)（內似咖(ka)啡飲(yin)(yin)(yin)品(pin)形式(shi)(shi)(shi)）的(de)(de)如今(jin)中(zhong)(zhong)葯丹(dan)參(can)(can)飲(yin)(yin)(yin)，與會(hui)口服(fu)(fu)藥丹(dan)參(can)(can)飲(yin)(yin)(yin)內似的(de)(de)生產制(zhi)造(zao)部(bu)(bu)門形式(shi)(shi)(shi)，本總部(bu)(bu)生產制(zhi)造(zao)部(bu)(bu)門部(bu)(bu)門依本類(lei)中(zhong)(zhong)葯丹(dan)參(can)(can)飲(yin)(yin)(yin)的(de)(de)因素，系統軟件地生產制(zhi)造(zao)部(bu)(bu)門的(de)(de)新(xin)技術泡(pao)服(fu)(fu)丹(dan)參(can)(can)飲(yin)(yin)(yin)成(cheng)品(pin)類(lei)別，可會(hui)用(yong)(yong)(yong)滾(gun)水(shui)沖奶粉飲(yin)(yin)(yin)用(yong)(yong)(yong)（也可與藥方(fang)一般丹(dan)參(can)(can)飲(yin)(yin)(yin)配(pei)量(liang)同煎應用(yong)(yong)(yong)），大局限(xian)地恢復(fu)固(gu)有(you)(you)(you)的(de)(de)更有(you)(you)(you)效營養成(cheng)分并改善臨床實踐(jian)效用(yong)(yong)(yong)。

中(zhong)國有(you)蘇軒堂藥(yao)業首席總裁履行(xing)官周峰叔叔評介道：“用(yong)持續(xu)保持不斷的生(sheng)(sheng)產加工(gong)(gong)制(zhi)造和生(sheng)(sheng)產加工(gong)(gong)近(jin)代草(cao)(cao)藥(yao)中(zhong)要(yao)制(zhi)劑(ji)，將遠遠利于(yu)讓(rang)小編在創新(xin)引領(ling)近(jin)代草(cao)(cao)藥(yao)中(zhong)要(yao)制(zhi)劑(ji)的新(xin)的產品生(sheng)(sheng)產加工(gong)(gong)制(zhi)造和追隨挺高安全性能的新(xin)的產品方便作成持續(xu)保持的奮發努力(li)。讓(rang)小編想必，這將進步驟(zou)發展讓(rang)小編會服食和泡服草(cao)(cao)藥(yao)中(zhong)要(yao)制(zhi)劑(ji)的新(xin)的產品的行(xing)業市(shi)場(chang)銷售額(e)。”

 

在我國蘇軒堂藥業總部股票有現總部間介：

蘇軒堂藥業解散于2005年，總部基地坐落中國國深圳省泰州市，就一家努力于中醫草藥制劑科研、生產制造、營銷戰略和產品的創新發展型中醫制作藥品大公司，中醫草藥制劑就一種經代加工可供安全使用的中醫。欲知曉越來越多圖片信息，請訪問xtjcw.cn。

 

應急港聲明怎么寫

本(ben)(ben)(ben)中(zhong)(zhong)央(yang)講話稿包含(han)了《1995年個人(ren)(ren)與(yu)個人(ren)(ren)證券基(ji)金(jin)上(shang)(shang)訴改(gai)(gai)變國際公約》(Private Securities Litigation Reform Act of 1995)所(suo)解釋的(de)(de)(de)高(gao)瞻性(xing)(xing)(xing)(xing)(xing)自我(wo)(wo)陳(chen)詞(ci)。高(gao)瞻性(xing)(xing)(xing)(xing)(xing)自我(wo)(wo)陳(chen)詞(ci)隸(li)屬(shu)(shu)于(yu)對於計劃怎么寫、對方(fang)(fang)、對方(fang)(fang)、方(fang)(fang)法、的(de)(de)(de)前景生(sheng)(sheng)(sheng)活行(xing)為或(huo)(huo)工(gong)作凈(jing)利潤的(de)(de)(de)自我(wo)(wo)陳(chen)詞(ci)，或(huo)(huo)者(zhe)主要猜(cai)測和(he)(he)(he)(he)別(bie)的(de)(de)(de)不(bu)(bu)(bu)史(shi)(shi)上(shang)(shang)事實(shi)情況的(de)(de)(de)自我(wo)(wo)陳(chen)詞(ci)。該(gai)司適(shi)用就其“幾率(lv)”、“將”、“用意”、“大概(gai)”、“深(shen)信(xin)不(bu)(bu)(bu)疑”、“期(qi)(qi)(qi)望會(hui)(hui)”、“期(qi)(qi)(qi)望會(hui)(hui)”“猜(cai)測”、“想必(bi)”或(huo)(huo)與(yu)史(shi)(shi)上(shang)(shang)行(xing)為息(xi)(xi)息(xi)(xi)有(you)關(guan)的(de)(de)(de)的(de)(de)(de)之類呈(cheng)現時都(dou)隸(li)屬(shu)(shu)于(yu)高(gao)瞻性(xing)(xing)(xing)(xing)(xing)自我(wo)(wo)陳(chen)詞(ci)。按照比喻，該(gai)司對於達到擬議(yi)的(de)(de)(de)私募(mu)投(tou)資的(de)(de)(de)配股的(de)(de)(de)聲(sheng)明書(shu)是高(gao)瞻性(xing)(xing)(xing)(xing)(xing)的(de)(de)(de)。高(gao)瞻性(xing)(xing)(xing)(xing)(xing)自我(wo)(wo)陳(chen)詞(ci)不(bu)(bu)(bu)的(de)(de)(de)前景生(sheng)(sheng)(sheng)活工(gong)作凈(jing)利潤的(de)(de)(de)擔保，設及(ji)危害性(xing)(xing)(xing)(xing)(xing)和(he)(he)(he)(he)不(bu)(bu)(bu)知道(dao)(dao)性(xing)(xing)(xing)(xing)(xing)，這危害性(xing)(xing)(xing)(xing)(xing)和(he)(he)(he)(he)不(bu)(bu)(bu)知道(dao)(dao)性(xing)(xing)(xing)(xing)(xing)幾率(lv)誘(you)發事實(shi)沒想到與(yu)司在高(gao)瞻性(xing)(xing)(xing)(xing)(xing)統計報表(biao)中(zhong)(zhong)研討(tao)(tao)的(de)(de)(de)期(qi)(qi)(qi)望會(hui)(hui)大不(bu)(bu)(bu)相等。這自我(wo)(wo)陳(chen)詞(ci)遭(zao)受到不(bu)(bu)(bu)知道(dao)(dao)的(de)(de)(de)原(yuan)則和(he)(he)(he)(he)危害性(xing)(xing)(xing)(xing)(xing)的(de)(de)(de)損害，隸(li)屬(shu)(shu)于(yu)但不(bu)(bu)(bu)僅(jin)限：司的(de)(de)(de)對方(fang)(fang)和(he)(he)(he)(he)方(fang)(fang)法；司的(de)(de)(de)的(de)(de)(de)前景生(sheng)(sheng)(sheng)活業(ye)務保障(zhang)(zhang)不(bu)(bu)(bu)斷發展；貨品(pin)和(he)(he)(he)(he)業(ye)務保障(zhang)(zhang)實(shi)際需求及(ji)使(shi)用者(zhe)認可度；水平(ping)發生(sheng)(sheng)(sheng)改(gai)(gai)變；華人(ren)(ren)醫療器械市(shi)揚，很(hen)大是中(zhong)(zhong)藥才(cai)中(zhong)(zhong)藥材市(shi)揚的(de)(de)(de)增長額(e)；公信(xin)力(li)和(he)(he)(he)(he)國產品(pin)牌(pai)；激烈競爭和(he)(he)(he)(he)售(shou)價(jia)的(de)(de)(de)損害；中(zhong)(zhong)央(yang)政府法律規(gui)范(fan)；司所(suo)業(ye)務保障(zhang)(zhang)的(de)(de)(de)華人(ren)(ren)和(he)(he)(he)(he)國際市(shi)揚的(de)(de)(de)總體目標(biao)經濟性(xing)(xing)(xing)(xing)(xing)和(he)(he)(he)(he)商(shang)業(ye)圈經濟條(tiao)件的(de)(de)(de)價(jia)格波(bo)動或(huo)(huo)者(zhe)司向證券基(ji)金(jin)基(ji)金(jin)刷(shua)卡(ka)消(xiao)費委會(hui)(hui)會(hui)(hui)出(chu)具的(de)(de)(de)評估中(zhong)(zhong)談(tan)論的(de)(de)(de)任意左(zuo)右所(suo)述(shu)和(he)(he)(he)(he)別(bie)的(de)(de)(de)危害性(xing)(xing)(xing)(xing)(xing)的(de)(de)(de)內(nei)在的(de)(de)(de)或(huo)(huo)有(you)關(guan)的(de)(de)(de)猜(cai)測。綜上(shang)(shang)所(suo)述(shu)左(zuo)右原(yuan)故，人(ren)(ren)們勸勉投(tou)資的(de)(de)(de)者(zhe)不(bu)(bu)(bu)必(bi)太(tai)過依賴(lai)于(yu)本(ben)(ben)(ben)社會(hui)(hui)通訊稿中(zhong)(zhong)的(de)(de)(de)任意高(gao)瞻性(xing)(xing)(xing)(xing)(xing)自我(wo)(wo)陳(chen)詞(ci)。該(gai)司出(chu)具給(gei)新加(jia)坡證券基(ji)金(jin)基(ji)金(jin)刷(shua)卡(ka)消(xiao)費委會(hui)(hui)會(hui)(hui)的(de)(de)(de)資料目錄(lu)中(zhong)(zhong)還研討(tao)(tao)了別(bie)的(de)(de)(de)的(de)(de)(de)原(yuan)則，這資料目錄(lu)可在www.sec.gov上(shang)(shang)調取(qu)。企業(ye)不(bu)(bu)(bu)會(hui)(hui)權利在許(xu)多文(wen)本(ben)(ben)(ben)上(shang)(shang)報后期(qi)(qi)(qi)基(ji)于(yu)某致(zhi)死案或(huo)(huo)問題所(suo)產生(sheng)(sheng)(sheng)的(de)(de)(de)許(xu)多高(gao)瞻性(xing)(xing)(xing)(xing)(xing)證明函的(de)(de)(de)優化做發表(biao)步長。

 

認知更好地信心，請鏈接：

集團數據給出:
周峰，首席總裁執行工作官
電子無線而且郵件: fzhou@xtjcw.cn或 ir@xtjcw.cn
手機 : 86-523-8629-9087

• 上一篇：中國蘇軒堂藥業股份有限公司宣布擬議的普通股承銷公開發行和可認購普通股的預購認股權證
• 下一篇：中國蘇軒堂藥業股份有限公司獲得新藥品生產許可證并通過GMP合規性檢查